Venus Concept (NASDAQ:VERO – Get Free Report) and Boston Scientific (NYSE:BSX – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.
Volatility and Risk
Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
Valuation and Earnings
This table compares Venus Concept and Boston Scientific”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Venus Concept | $58.88 million | 0.01 | -$47.00 million | ($48.84) | -0.01 |
| Boston Scientific | $21.07 billion | 3.12 | $2.90 billion | $2.36 | 19.22 |
Boston Scientific has higher revenue and earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
87.4% of Venus Concept shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 28.0% of Venus Concept shares are owned by company insiders. Comparatively, 0.3% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Venus Concept and Boston Scientific, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Venus Concept | 1 | 0 | 0 | 0 | 1.00 |
| Boston Scientific | 2 | 8 | 20 | 1 | 2.65 |
Boston Scientific has a consensus target price of $61.43, indicating a potential upside of 35.42%. Given Boston Scientific’s stronger consensus rating and higher probable upside, analysts clearly believe Boston Scientific is more favorable than Venus Concept.
Profitability
This table compares Venus Concept and Boston Scientific’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Venus Concept | -92.76% | -1,904.25% | -85.22% |
| Boston Scientific | 16.62% | 18.61% | 10.58% |
Summary
Boston Scientific beats Venus Concept on 14 of the 15 factors compared between the two stocks.
About Venus Concept
Venus Concept Inc. is a medical technology company that develops, commercializes and supports aesthetic and hair-restoration systems for physicians and other medical professionals. Its products are designed for procedures involving skin resurfacing, hair removal, skin tightening, body contouring and other cosmetic treatments. The company’s portfolio has included energy-based aesthetic platforms such as Venus Versa, Venus Viva and Venus Legacy, as well as robotic hair-restoration technology marketed under the NeoGraft and related brands.
About Boston Scientific
Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.
Receive News & Ratings for Venus Concept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venus Concept and related companies with MarketBeat.com's FREE daily email newsletter.
